vs

Side-by-side financial comparison of Charles River Laboratories (CRL) and Genpact LTD (G). Click either name above to swap in a different company.

Genpact LTD is the larger business by last-quarter revenue ($1.3B vs $995.8M, roughly 1.3× Charles River Laboratories). Genpact LTD runs the higher net margin — 11.4% vs -1.5%, a 12.9% gap on every dollar of revenue. On growth, Genpact LTD posted the faster year-over-year revenue change (6.7% vs 1.2%). Over the past eight quarters, Genpact LTD's revenue compounded faster (5.0% CAGR vs -1.5%).

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.

Genpact Ltd. is an American information technology services, consulting, and outsourcing company headquartered in New York City, New York. Founded in Gurgaon, India, and legally domiciled in Bermuda, Genpact employs more than 125,000 people and provides services to clients in over 30 countries worldwide. Genpact is listed on the NYSE and generated revenues of US$4.48 billion in 2023.

CRL vs G — Head-to-Head

Bigger by revenue
G
G
1.3× larger
G
$1.3B
$995.8M
CRL
Growing faster (revenue YoY)
G
G
+5.5% gap
G
6.7%
1.2%
CRL
Higher net margin
G
G
12.9% more per $
G
11.4%
-1.5%
CRL
Faster 2-yr revenue CAGR
G
G
Annualised
G
5.0%
-1.5%
CRL

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CRL
CRL
G
G
Revenue
$995.8M
$1.3B
Net Profit
$-14.8M
$148.0M
Gross Margin
36.4%
Operating Margin
12.0%
15.3%
Net Margin
-1.5%
11.4%
Revenue YoY
1.2%
6.7%
Net Profit YoY
-157.2%
13.1%
EPS (diluted)
$-0.30
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRL
CRL
G
G
Q1 26
$995.8M
$1.3B
Q4 25
$994.2M
$1.3B
Q3 25
$1.0B
$1.3B
Q2 25
$1.0B
$1.3B
Q1 25
$984.2M
$1.2B
Q4 24
$1.0B
$1.2B
Q3 24
$1.0B
$1.2B
Q2 24
$1.0B
$1.2B
Net Profit
CRL
CRL
G
G
Q1 26
$-14.8M
$148.0M
Q4 25
$-276.6M
$143.1M
Q3 25
$54.4M
$145.8M
Q2 25
$52.3M
$132.7M
Q1 25
$25.5M
$130.9M
Q4 24
$-214.5M
$141.9M
Q3 24
$69.7M
$132.8M
Q2 24
$94.1M
$122.0M
Gross Margin
CRL
CRL
G
G
Q1 26
36.4%
Q4 25
36.6%
Q3 25
36.4%
Q2 25
35.9%
Q1 25
35.3%
Q4 24
35.7%
Q3 24
34.6%
35.6%
Q2 24
34.5%
35.4%
Operating Margin
CRL
CRL
G
G
Q1 26
12.0%
15.3%
Q4 25
-28.5%
14.8%
Q3 25
13.3%
14.8%
Q2 25
9.7%
14.3%
Q1 25
7.6%
15.1%
Q4 24
-16.7%
15.2%
Q3 24
11.6%
15.0%
Q2 24
14.8%
14.5%
Net Margin
CRL
CRL
G
G
Q1 26
-1.5%
11.4%
Q4 25
-27.8%
10.8%
Q3 25
5.4%
11.3%
Q2 25
5.1%
10.6%
Q1 25
2.6%
10.8%
Q4 24
-21.4%
11.4%
Q3 24
6.9%
11.0%
Q2 24
9.2%
10.4%
EPS (diluted)
CRL
CRL
G
G
Q1 26
$-0.30
$0.86
Q4 25
$-5.57
$0.82
Q3 25
$1.10
$0.83
Q2 25
$1.06
$0.75
Q1 25
$0.50
$0.73
Q4 24
$-4.17
$0.80
Q3 24
$1.33
$0.74
Q2 24
$1.74
$0.67

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRL
CRL
G
G
Cash + ST InvestmentsLiquidity on hand
$191.8M
$928.1M
Total DebtLower is stronger
$1.5B
Stockholders' EquityBook value
$2.9B
$2.5B
Total Assets
$7.7B
$5.6B
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRL
CRL
G
G
Q1 26
$191.8M
$928.1M
Q4 25
$213.8M
$1.2B
Q3 25
$207.1M
$740.8M
Q2 25
$182.8M
$663.3M
Q1 25
$229.4M
$561.6M
Q4 24
$194.6M
$671.6M
Q3 24
$210.2M
$1.0B
Q2 24
$179.2M
$914.2M
Total Debt
CRL
CRL
G
G
Q1 26
$1.5B
Q4 25
$2.1B
$1.5B
Q3 25
$2.2B
$1.2B
Q2 25
$2.3B
$1.2B
Q1 25
$2.5B
$1.2B
Q4 24
$2.2B
$1.2B
Q3 24
$2.3B
$1.6B
Q2 24
$2.4B
$1.6B
Stockholders' Equity
CRL
CRL
G
G
Q1 26
$2.9B
$2.5B
Q4 25
$3.2B
$2.5B
Q3 25
$3.4B
$2.5B
Q2 25
$3.4B
$2.6B
Q1 25
$3.2B
$2.5B
Q4 24
$3.5B
$2.4B
Q3 24
$3.8B
$2.4B
Q2 24
$3.7B
$2.3B
Total Assets
CRL
CRL
G
G
Q1 26
$7.7B
$5.6B
Q4 25
$7.1B
$5.8B
Q3 25
$7.5B
$5.4B
Q2 25
$7.6B
$5.3B
Q1 25
$7.6B
$4.9B
Q4 24
$7.5B
$5.0B
Q3 24
$8.0B
$5.3B
Q2 24
$7.9B
$5.2B
Debt / Equity
CRL
CRL
G
G
Q1 26
0.62×
Q4 25
0.68×
0.60×
Q3 25
0.64×
0.47×
Q2 25
0.70×
0.47×
Q1 25
0.79×
0.50×
Q4 24
0.65×
0.51×
Q3 24
0.62×
0.68×
Q2 24
0.65×
0.70×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRL
CRL
G
G
Operating Cash FlowLast quarter
$41.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
5.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRL
CRL
G
G
Q1 26
$41.1M
Q4 25
$147.5M
$286.7M
Q3 25
$213.8M
$308.4M
Q2 25
$204.6M
$177.4M
Q1 25
$171.7M
$40.4M
Q4 24
$159.4M
$203.2M
Q3 24
$251.8M
$228.5M
Q2 24
$193.5M
$209.3M
Free Cash Flow
CRL
CRL
G
G
Q1 26
Q4 25
$58.6M
$269.0M
Q3 25
$178.2M
$292.0M
Q2 25
$169.3M
$155.1M
Q1 25
$112.4M
$18.5M
Q4 24
$83.7M
$183.5M
Q3 24
$213.1M
$208.7M
Q2 24
$154.0M
$190.0M
FCF Margin
CRL
CRL
G
G
Q1 26
Q4 25
5.9%
20.4%
Q3 25
17.7%
22.6%
Q2 25
16.4%
12.4%
Q1 25
11.4%
1.5%
Q4 24
8.4%
14.7%
Q3 24
21.1%
17.2%
Q2 24
15.0%
16.2%
Capex Intensity
CRL
CRL
G
G
Q1 26
5.6%
Q4 25
8.9%
1.3%
Q3 25
3.5%
1.3%
Q2 25
3.4%
1.8%
Q1 25
6.0%
1.8%
Q4 24
7.5%
1.6%
Q3 24
3.8%
1.6%
Q2 24
3.8%
1.6%
Cash Conversion
CRL
CRL
G
G
Q1 26
Q4 25
2.00×
Q3 25
3.93×
2.11×
Q2 25
3.91×
1.34×
Q1 25
6.74×
0.31×
Q4 24
1.43×
Q3 24
3.61×
1.72×
Q2 24
2.06×
1.72×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRL
CRL

Service revenue$798.2M80%
Product revenue$197.7M20%

G
G

Core Business Services$950.8M73%
Advanced Technology Solutions$345.2M27%

Related Comparisons